Quarterly ResultMay 20, 2026, 07:02 AM
Roivant reaches $2.25B Moderna settlement; IMVT-1402 shows strong D2T RA data
AI Summary
Roivant Sciences announced a $2.25 billion global settlement with Moderna, resolving all pending patent-infringement litigation, with $950 million payable in July 2026. The company also reported positive Period 1 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, showing a 72.7% ACR20 response rate. Additionally, brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis and is expected to launch commercially in dermatomyositis by September 2026. Roivant ended the fiscal year with $4.3 billion in cash, cash equivalents, and marketable securities, while discontinuing batoclimab development.
Key Highlights
- Global settlement with Moderna for $2.25 billion, ending all patent-infringement litigation.
- Moderna to pay Genevant and Arbutus $950 million by July 2026, with an additional $1.3 billion contingent.
- IMVT-1402 showed 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in D2T RA trial.
- Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis.
- Commercial launch of brepocitinib in dermatomyositis expected by the end of September 2026.
- Consolidated cash, cash equivalents, and marketable securities totaled $4.3 billion as of March 31, 2026.
- Income from continuing operations, net of tax, was $355.7 million for Q4 2026, compared to a $252.4 million loss in Q4 2025.
- Discontinued further development of batoclimab across all indications following Phase 3 TED trial results.
Price Impact
More from ROIV